DK0973392T3 - Divalente sulfonyl-aryl eller heteroarylhydroxamsyreforbindelser - Google Patents

Divalente sulfonyl-aryl eller heteroarylhydroxamsyreforbindelser

Info

Publication number: DK0973392T3
Authority: DK; Denmark
Prior art keywords: hydroxamic acid; aryl; acid compounds; sulfonyl; heteroaryl hydroxamic
Prior art date: 1997-03-04

Application number

DK98911481T

Other languages

English (en)

Inventor

Joseph J Mcdonald

Thomas E Barta

Daniel P Becker

Louis J Bedell

Shashidhar N Rao

John N Freskos

Brent V Mischke

Original Assignee

Monsanto Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-04

Filing date

1998-03-04

Publication date

2004-03-29

1998-03-04 Application filed by Monsanto Co filed Critical Monsanto Co

2004-03-29 Application granted granted Critical

2004-03-29 Publication of DK0973392T3 publication Critical patent/DK0973392T3/da

Links

239000002253 acid Substances 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 title abstract 3
-1 heteroaryl hydroxamic Chemical compound 0.000 title 1
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 abstract 2
102000005741 Metalloproteases Human genes 0.000 abstract 2
108010006035 Metalloproteases Proteins 0.000 abstract 2
125000003118 aryl group Chemical group 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
125000001072 heteroaryl group Chemical group 0.000 abstract 2
239000011159 matrix material Substances 0.000 abstract 2
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
230000001575 pathological effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Hematology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Nutrition Science (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK98911481T 1997-03-04 1998-03-04 Divalente sulfonyl-aryl eller heteroarylhydroxamsyreforbindelser DK0973392T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3518297P	1997-03-04	1997-03-04
PCT/US1998/004300 WO1998038859A1 (en)	1997-03-04	1998-03-04	Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds

Publications (1)

Publication Number	Publication Date
DK0973392T3 true DK0973392T3 (da)	2004-03-29

Family

ID=21881145

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK98911481T DK0973392T3 (da)	1997-03-04	1998-03-04	Divalente sulfonyl-aryl eller heteroarylhydroxamsyreforbindelser

Country Status (19)

Country	Link
US (3)	US6380258B2 (da)
EP (4)	EP0984959B1 (da)
JP (4)	JP2002513407A (da)
KR (3)	KR20000075954A (da)
CN (3)	CN1253474A (da)
AT (1)	ATE254599T1 (da)
AU (2)	AU750303B2 (da)
BR (2)	BR9808166A (da)
CA (4)	CA2283145A1 (da)
DE (1)	DE69819878T2 (da)
DK (1)	DK0973392T3 (da)
EA (1)	EA199900792A1 (da)
ES (2)	ES2209122T3 (da)
IL (3)	IL131493A (da)
NO (1)	NO315647B1 (da)
NZ (1)	NZ337326A (da)
PL (1)	PL335732A1 (da)
PT (1)	PT973392E (da)
WO (1)	WO1998038859A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6747027B1 (en)	1996-07-22	2004-06-08	Pharmacia Corporation	Thiol sulfonamide metalloprotease inhibitors
US6696449B2 (en)	1997-03-04	2004-02-24	Pharmacia Corporation	Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US7115632B1 (en) *	1999-05-12	2006-10-03	G. D. Searle & Co.	Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6794511B2 (en)	1997-03-04	2004-09-21	G. D. Searle	Sulfonyl aryl or heteroaryl hydroxamic acid compounds
NZ337326A (en)	1997-03-04	2001-05-25	Monsanto Co	Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds to inhibit the activity of matrix metalloproteinases
KR20010032319A (ko) *	1997-11-21	2001-04-16	로렌스 티. 마이젠헬더	매트릭스 메탈로프로테이나제 억제제로서 β-술포닐히드록스아민산의 α-히드록시, -아미노 및 -플루오로유도체
WO2000037433A1 (en) *	1998-12-18	2000-06-29	Abbott Laboratories	Inhibitors of matrix metalloproteinases
US6800646B1 (en)	1999-02-08	2004-10-05	Pharmacia Corporation	Sulfamato hydroxamic acid metalloprotease inhibitor
CA2367963A1 (en) *	1999-03-22	2000-09-28	Darwin Discovery Limited	Hydroxamic and carboxylic acid derivatives
AU781339B2 (en) *	1999-05-12	2005-05-19	G.D. Searle & Co.	Hydroxamic acid derivatives as matrix metalloprotease inhibitors
US6808902B1 (en)	1999-11-12	2004-10-26	Amgen Inc.	Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP1748046A3 (en) *	1999-11-23	2007-08-22	Methylgene, Inc.	Inhibitors of histone deacetylase
JP4975941B2 (ja)	2000-09-29	2012-07-11	トポターゲットユーケーリミテッド	（ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
EP1335898B1 (en)	2000-09-29	2005-11-23	TopoTarget UK Limited	Carbamic acid compounds comprising an amide linkage as hdac inhibitors
EP2295081B1 (en)	2001-06-26	2018-10-31	Amgen Inc.	Antibodies to OPGL
US6683078B2 (en) *	2001-07-19	2004-01-27	Pharmacia Corporation	Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
FR2827859B1 (fr)	2001-07-30	2005-09-23	Lipha	Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
NZ536116A (en) *	2002-04-03	2007-01-26	Topotarget Uk Ltd	Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
WO2003091247A2 (en)	2002-04-25	2003-11-06	Pharmacia Corporation	Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
GB0226855D0 (en) *	2002-11-18	2002-12-24	Queen Mary & Westfield College	Histone deacetylase inhibitors
AU2003300076C1 (en)	2002-12-30	2010-03-04	Angiotech International Ag	Drug delivery from rapid gelling polymer composition
US8088737B2 (en)	2003-04-04	2012-01-03	Incyte Corporation	Compositions, methods and kits relating to Her-2 cleavage
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
WO2005092844A1 (en) *	2004-03-22	2005-10-06	Southern Research Institute	Nonpeptide inhibitors of matrix metalloproteinases
US20050250789A1 (en) *	2004-04-20	2005-11-10	Burns David M	Hydroxamic acid derivatives as metalloprotease inhibitors
US7348437B2 (en) *	2004-06-01	2008-03-25	The Scripps Research Institute	Proteomic analysis
US20050277897A1 (en) *	2004-06-14	2005-12-15	Ghannoum Ziad R	Handpiece tip
TW200700392A (en) *	2005-03-16	2007-01-01	Astrazeneca Ab	Novel compounds
CN101273013B (zh) *	2005-09-27	2013-06-12	盐野义制药株式会社	具有pgd2受体拮抗活性的磺酰胺衍生物
AU2009310952B2 (en) *	2008-10-27	2015-04-30	Mitsubishi Tanabe Pharma Corporation	Novel amide derivative and use thereof as medicine
MX337575B (es)	2009-10-09	2016-03-10	Zafgen Corp	Compuestos de sulfona y métodos para lafabricación y uso de éstos.
AU2011281037B2 (en)	2010-07-22	2014-11-27	Zafgen, Inc.	Tricyclic compounds and methods of making and using same
WO2012103333A1 (en)	2011-01-26	2012-08-02	Zafgen Corporation	Tetrazole compounds and methods of making and using same
SG194812A1 (en)	2011-05-06	2013-12-30	Zafgen Inc	Partially saturated tricyclic compounds and methods of making and using same
CN103748094B (zh)	2011-05-06	2016-06-29	扎夫根股份有限公司	三环磺酰胺化合物及其制备和使用方法
US9242997B2 (en)	2011-05-06	2016-01-26	Zafgen, Inc.	Tricyclic pyrazole sulphonamide compunds and methods of making and using same
CN104892457B (zh) *	2011-07-25	2017-07-28	中国医学科学院医药生物技术研究所	一种异羟肟酸类衍生物、其药物组合物、制备方法及用途
US10531655B2 (en)	2011-12-02	2020-01-14	The Regents Of The University Of California	Reperfusion protection solution and uses thereof
WO2013109735A1 (en)	2012-01-18	2013-07-25	Zafgen, Inc.	Tricyclic sulfone compounds and methods of making and using same
BR112014017673A8 (pt)	2012-01-18	2017-07-11	Zafgen Inc	Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
BR112015010196A2 (pt)	2012-11-05	2017-07-11	Zafgen Inc	métodos de tratar doença do fígado
MX2015005733A (es)	2012-11-05	2016-02-10	Zafgen Inc	Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
KR20150079952A (ko)	2012-11-05	2015-07-08	자프겐 인크.	트리시클릭 화합물 및 그의 제조 및 사용 방법
ES2620323T3 (es) *	2012-11-09	2017-06-28	Unilever N.V.	Composición y método para tratar sustratos
US9840520B2 (en)	2014-05-14	2017-12-12	The Regents Of The University Of Colorado, A Body Corporate	Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
AU2017232391C1 (en) *	2016-03-17	2022-12-22	Xeniopro GmbH	Enhancers of notch signaling and their use in the treatment of cancers and malignancies medicable by upregulation of notch
WO2020006384A1 (en) *	2018-06-29	2020-01-02	Loyola University Of Chicago	Carborane hydroxamic acid matrix metalloproteinase inhibitors and agents for boron neutron capture therapy
CN111217722B (zh) *	2020-03-06	2024-01-02	华东理工大学	偶氮芳基脲类衍生物及其制备方法和应用
CN116102391B (zh) *	2023-01-06	2025-01-28	湖大粤港澳大湾区创新研究院(广州增城)	二硫转移试剂及其合成与应用
EP4732934A1 (en) *	2024-10-23	2026-04-29	SK Innovation Co., Ltd.	Carbon dioxide absorbent, method of preparing the same, and carbon dioxide separation method using the same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4148801A (en)	1978-07-03	1979-04-10	American Home Products Corporation	3-[(Chlorophenylsulfonyl)methyl]-1,2,4-oxadiazole-5-carboxylic acid derivatives
US4595700A (en)	1984-12-21	1986-06-17	G. D. Searle & Co.	Thiol based collagenase inhibitors
US5103014A (en)	1987-09-30	1992-04-07	American Home Products Corporation	Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
GB2212153B (en) *	1987-11-16	1992-01-15	Squibb & Sons Inc	Phenyl hydroxamic acids
GB8827305D0 (en) *	1988-11-23	1988-12-29	British Bio Technology	Compounds
US5527945A (en) *	1989-02-10	1996-06-18	Basf Aktiengesellschaft	Diphenylheteroalkyl derivatives, the preparation thereof and drugs and cosmetics prepared therefrom
EP0493925B1 (en) *	1990-12-17	1997-11-05	Sankyo Company Limited	Pyrazole derivatives having herbicidal activity, their preparation and their use
AU3899193A (en)	1992-04-07	1993-11-08	British Bio-Technology Limited	Hydroxamic acid based collagenase and cytokine inhibitors
US5376664A (en)	1992-07-27	1994-12-27	The Du Pont Merck Pharmaceutical Company	Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
US5506242A (en) *	1993-01-06	1996-04-09	Ciba-Geigy Corporation	Arylsufonamido-substituted hydroxamic acids
US5552419A (en)	1993-01-06	1996-09-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5455258A (en) *	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5646167A (en)	1993-01-06	1997-07-08	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamix acids
GB9307956D0 (en)	1993-04-17	1993-06-02	Walls Alan J	Hydroxamic acid derivatives
GB9320660D0 (en) *	1993-10-07	1993-11-24	British Bio Technology	Inhibition of cytokine production
GB9323165D0 (en)	1993-11-10	1994-01-05	Chiros Ltd	Compounds
WO1995029892A1 (en)	1994-04-28	1995-11-09	The Du Pont Merck Pharmaceutical Company	Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
GB9416897D0 (en)	1994-08-20	1994-10-12	British Biotech Pharm	Metalloproteinase inhibitors
CZ288436B6 (en)	1994-10-05	2001-06-13	Darwin Discovery Ltd	Peptidyl derivatives, their therapeutic use as inhibitors of metalloproteinases and pharmaceutical preparation in which they are comprised
US5789434A (en) *	1994-11-15	1998-08-04	Bayer Corporation	Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
ES2233275T3 (es)	1995-12-08	2005-06-16	Agouron Pharmaceuticals, Inc.	Intermediarios que sirven para la preparacion de inhibidores de metaloproteinasas.
ATE225343T1 (de) *	1995-12-20	2002-10-15	Hoffmann La Roche	Matrix-metalloprotease inhibitoren
PT871439E (pt) *	1996-01-02	2004-08-31	Aventis Pharma Inc	Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo)
WO1997049679A1 (en)	1996-06-27	1997-12-31	Ono Pharmaceutical Co., Ltd.	Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
WO1998005635A1 (en) *	1996-08-07	1998-02-12	Darwin Discovery Limited	Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
KR20000048639A (ko) *	1996-09-27	2000-07-25	로렌스 티. 마이젠헬더	매트릭스 메탈로프로테이나제 억제제인 베타-술포닐 히드록삼산
ATE205306T1 (de) *	1997-01-13	2001-09-15	Fuji Photo Film Co Ltd	Wärmeentwickelbares, photoempfindliches farbmaterial
JP2000507975A (ja) *	1997-02-07	2000-06-27	ファイザー・インク	Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
YU40999A (sh) *	1997-02-27	2002-06-19	American Cyanamid Company	N-hidroksi-2-(alkil,aril ili heteroaril sulfanil,sulfinil ili sulfonil)-3-supstituisani alkil,aril ili heteroarilamidi, kao inhibitori za matrične metaloproteinaze
NZ337326A (en)	1997-03-04	2001-05-25	Monsanto Co	Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds to inhibit the activity of matrix metalloproteinases
US20010014688A1 (en) *	1997-11-14	2001-08-16	Thomas E. Barta	Aromatic sulfone hydroxamic acid metalloprotease inhibitor

1998
- 1998-03-04 NZ NZ337326A patent/NZ337326A/en unknown
- 1998-03-04 PT PT98911481T patent/PT973392E/pt unknown
- 1998-03-04 CA CA002283145A patent/CA2283145A1/en not_active Abandoned
- 1998-03-04 EP EP98910177A patent/EP0984959B1/en not_active Expired - Lifetime
- 1998-03-04 KR KR1019997008036A patent/KR20000075954A/ko not_active Ceased
- 1998-03-04 WO PCT/US1998/004300 patent/WO1998038859A1/en not_active Ceased
- 1998-03-04 BR BR9808166-7A patent/BR9808166A/pt not_active Application Discontinuation
- 1998-03-04 EP EP98911481A patent/EP0973392B1/en not_active Expired - Lifetime
- 1998-03-04 JP JP53879698A patent/JP2002513407A/ja not_active Abandoned
- 1998-03-04 AT AT98911481T patent/ATE254599T1/de not_active IP Right Cessation
- 1998-03-04 JP JP53878098A patent/JP2002515901A/ja not_active Abandoned
- 1998-03-04 IL IL13149398A patent/IL131493A/en not_active IP Right Cessation
- 1998-03-04 JP JP53798598A patent/JP2002515900A/ja not_active Abandoned
- 1998-03-04 IL IL13149498A patent/IL131494A/xx not_active IP Right Cessation
- 1998-03-04 DE DE69819878T patent/DE69819878T2/de not_active Expired - Fee Related
- 1998-03-04 ES ES98910177T patent/ES2209122T3/es not_active Expired - Lifetime
- 1998-03-04 CN CN98804577A patent/CN1253474A/zh active Pending
- 1998-03-04 AU AU66865/98A patent/AU750303B2/en not_active Ceased
- 1998-03-04 BR BR9808214-0A patent/BR9808214A/pt not_active IP Right Cessation
- 1998-03-04 KR KR1019997008037A patent/KR20000075955A/ko not_active Ceased
- 1998-03-04 IL IL13149598A patent/IL131495A0/xx unknown
- 1998-03-04 ES ES98911481T patent/ES2206903T3/es not_active Expired - Lifetime
- 1998-03-04 CN CN98804575A patent/CN1105114C/zh not_active Expired - Fee Related
- 1998-03-04 CA CA002282318A patent/CA2282318A1/en not_active Abandoned
- 1998-03-04 JP JP53879998A patent/JP2001518081A/ja not_active Abandoned
- 1998-03-04 DK DK98911481T patent/DK0973392T3/da active
- 1998-03-04 KR KR1019997008028A patent/KR20000075946A/ko not_active Ceased
- 1998-03-04 EP EP98908949A patent/EP0983257A4/en not_active Withdrawn
- 1998-03-04 CA CA002283272A patent/CA2283272A1/en not_active Abandoned
- 1998-03-04 CN CN98804628A patent/CN1254337A/zh active Pending
- 1998-03-04 US US09/230,209 patent/US6380258B2/en not_active Expired - Fee Related
- 1998-03-04 EA EA199900792A patent/EA199900792A1/ru unknown
- 1998-03-04 CA CA002283275A patent/CA2283275A1/en not_active Abandoned
- 1998-03-04 PL PL98335732A patent/PL335732A1/xx unknown
- 1998-03-04 EP EP98908964A patent/EP0983258A4/en not_active Withdrawn
- 1998-03-04 AU AU65424/98A patent/AU750130B2/en not_active Ceased
1999
- 1999-09-02 NO NO19994252A patent/NO315647B1/no unknown
2001
- 2001-11-29 US US09/997,552 patent/US6656954B2/en not_active Expired - Fee Related
2003
- 2003-10-27 US US10/695,278 patent/US20040097487A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US6380258B2 (en)	2002-04-30
KR20000075954A (ko)	2000-12-26
EP0984959B1 (en)	2003-09-24
EP0973392B1 (en)	2003-11-19
NO994252L (no)	1999-09-02
IL131493A0 (en)	2001-01-28
EP0984959A4 (en)	2001-05-02
US20020103239A1 (en)	2002-08-01
EP0973392A1 (en)	2000-01-26
HK1027806A1 (en)	2001-01-23
AU737329B2 (en)	2001-08-16
ES2209122T3 (es)	2004-06-16
NZ337326A (en)	2001-05-25
JP2002515900A (ja)	2002-05-28
CA2282318A1 (en)	1998-09-11
KR20000075946A (ko)	2000-12-26
JP2001518081A (ja)	2001-10-09
IL131494A (en)	2005-06-19
CA2283272A1 (en)	1998-09-11
EP0983257A1 (en)	2000-03-08
AU750303B2 (en)	2002-07-18
EP0983257A4 (en)	2001-05-02
PT973392E (pt)	2004-04-30
WO1998038859A1 (en)	1998-09-11
DE69819878T2 (de)	2004-04-22
EP0973392A4 (en)	2001-05-02
CA2283145A1 (en)	1998-09-11
ATE254599T1 (de)	2003-12-15
AU6542498A (en)	1998-09-22
CN1254337A (zh)	2000-05-24
IL131495A0 (en)	2001-01-28
IL131494A0 (en)	2001-01-28
BR9808214A (pt)	2000-05-16
CA2283275A1 (en)	1998-09-11
JP2002513407A (ja)	2002-05-08
JP2002515901A (ja)	2002-05-28
ES2206903T3 (es)	2004-05-16
EP0983258A4 (en)	2001-01-17
AU6447898A (en)	1998-09-22
BR9808166A (pt)	2000-05-16
NO315647B1 (no)	2003-10-06
AU750130B2 (en)	2002-07-11
US6656954B2 (en)	2003-12-02
EA199900792A1 (ru)	2000-04-24
US20010020021A1 (en)	2001-09-06
AU6686598A (en)	1998-09-22
EP0984959A1 (en)	2000-03-15
US20040097487A1 (en)	2004-05-20
CN1253559A (zh)	2000-05-17
KR20000075955A (ko)	2000-12-26
IL131493A (en)	2004-05-12
EP0983258A1 (en)	2000-03-08
CN1105114C (zh)	2003-04-09
NO994252D0 (no)	1999-09-02
PL335732A1 (en)	2000-05-08
CN1253474A (zh)	2000-05-17
DE69819878D1 (de)	2003-12-24

Publication	Publication Date	Title
DK0973392T3 (da)	2004-03-29	Divalente sulfonyl-aryl eller heteroarylhydroxamsyreforbindelser
DK0977745T3 (da)	2005-03-14	Thioarylsulfonamidhydroxamsyreforbindelser
WO2001085680A3 (en)	2002-03-07	Sulfonyl aryl or heteroaryl hydroxamic acid compounds
AP2001002240A0 (en)	2001-09-30	Sufamato hydroxamic acid metalloprotease inhibitor.
NZ515197A (en)	2004-03-26	Hydroxamic acid derivatives useful as matrix metalloprotease inhibitors
DK1030836T3 (da)	2003-05-26	Hydroxam- og carboxylsyrederivater der har MMP- og TNF-inhiberende aktivitet
GB2303850A (en)	1997-03-05	Metalloproteinase inhibitors
CA2260337A1 (en)	1999-07-27	Therapeutic agents
DE69305642D1 (de)	1996-11-28	Injizierbares Arzneimittel und Satz, die Omoprazol oder verwandte Verbindungenenthalten
DE69737605D1 (de)	2007-05-24	Sulfonierte aminosäurederivate und metalloproteinase-inhibitoren, die diese enthalten
BR0309546A (pt)	2005-02-15	Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
HUP0202832A2 (hu)	2003-02-28	Új pirimidin-2,4,6-trion-származékok, alkalmazásuk, valamint az e vegyületeket tartalmazó gyógyászati készítmények
BR9811747A (pt)	2000-09-26	Inibidores de metaloproteinase de matriz à base de ácido malÈnico
BG46004A3 (bg)	1989-09-15	Метод за получаване на оптично активни 2-хлор-12-/3-диметиламин-2- метилпропил/12н-дибензо-/d,g//1,3,6/-диоксазоцини
MY141460A (en)	2010-04-30	Aromatic sulfone hydroxamic acid metalloprotease inhibitor